Latest stories on XNCR
XENCOR Maintains Buy Rating -- Price Target Raised to $40.00 by Truist Securities
GuruFocus64 · neutralanalyst
XENCOR Maintained by Wells Fargo -- Price Target Raised to $44.00
GuruFocus63 · neutralanalyst
Xencor (XNCR) Maintained by RBC Capital -- Price Target Raised to $43.00
GuruFocus63 · neutralanalyst
XNCR Maintained by Wedbush -- Price Target Raised to $45
GuruFocus63 · neutralanalyst
Xencor price target raised to $43 from $20 at RBC Capital
The Fly74 · bullishanalyst
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma - Slideshow
Seeking Alpha58 · neutralproduct/pr
Xencor Price Target Raised To 40 From 29 At Truist Thefly News 2
The Fly64 · neutralanalyst
Xencor price target raised to $40 from $29 at Truist
The Fly64 · neutralanalyst
Xencor price target raised to $45 from $30 at Wedbush
The Fly67 · bullishanalyst
Wells Fargo raises Xencor stock price target on kidney cancer data
Investing.com Analyst Ratings64 · neutralanalyst
Xencor soars 16% on encouraging early XmAb819 data
Seeking Alpha74 · bullishproduct/pr
Xencor: 'Strong Buy' On Positive XmAb819 ESMO Data ccRCC And Potential For FDA Accelerated Approval Pathway
Seeking Alpha74 · bullishanalyst
Xencor price target raised to $45 from $35 at Barclays
The Fly64 · neutralanalyst
Xencor, Inc. (XNCR) Discusses Phase 1 XmAb819 Results in Advanced Clear Cell Renal Cell Carcinoma Transcript
Seeking Alpha58 · neutralproduct/pr
Xencor Surges on Updated Phase 1 Data for XmAb819 as Phase 3 Plans Take Shape (XNCR)
Briefing.com74 · bullishproduct/pr
Xencor stock surges on positive cancer drug trial data
Investing.com Markets78 · bullishproduct/pr
Xencor Catapults, Breaking Out On 'Unprecedented,' 'Profound' Cancer Data
Investors.com78 · bullishproduct/pr
Xencor Catapults, Breaking Out On 'Unprecedented,' 'Profound' Cancer Data
Investors.com78 · bullishproduct/pr
Xencor advances XmAb819 solid-tumor T-cell engager
TipRanks63 · neutralproduct/pr
Xencor Inc (XNCR) files 8-K
SEC 8-K50 · neutralgeneral
At a glance: stocks gapping up premarket
Seeking Alpha63 · neutralgeneral
Xencor reports promising kidney cancer drug results, plans late-stage trial
Seeking Alpha74 · bullishproduct/pr
Xencor announces updated results from Phase 1 study of XmAb819
The Fly58 · neutralproduct/pr
Xencor to discuss results from Phase 1 study of XmAb819
The Fly56 · neutralproduct/pr